糖尿病網膜症の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

世界の糖尿病網膜症の市場規模は、2022年に86億1,000万米ドルに達し、2023～2030年の予測期間中にCAGR 7.26%で成長し、2030年には約150億8,000万米ドルに達すると予測されています。

糖尿病網膜症は糖尿病に関連する眼病で、目の奥にある光に敏感な組織である網膜に影響を与えます。糖尿病網膜症は、糖尿病患者の視力障害の顕著な原因となっています。糖尿病に伴う血糖値の上昇が網膜内の細い血管にダメージを与えることで、徐々に発症します。

市場力学

糖尿病網膜症市場は、糖尿病の世界の有病率の増加が主な要因となっています。糖尿病は依然として重大な健康上の懸念事項であるため、罹患率の上昇は糖尿病網膜症のリスクを抱える人口の増加に寄与し、診断および治療ソリューションの需要を促進しています。診断ツールや画像技術における技術的進歩が極めて重要な役割を果たしていることは、早期発見能力の向上に寄与していることからも明らかです。定期的な眼科検診が重視され、検診プログラムに遠隔医療が統合されたことで、特に十分なサービスを受けていない地域におけるアクセシビリティがさらに拡大しました。硝子体内注射や糖尿病黄斑浮腫を標的とした薬剤を含む医薬品の技術革新は、効果的な管理選択肢を提供することで市場の開拓に貢献しています。糖尿病管理における目の健康の重要性に関するヘルスケア専門家と患者の意識の高まりは、スクリーニングと早期介入の増加を促しています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは糖尿病網膜症の世界市場における各セグメントを包括的に評価することもできます。糖尿病網膜症産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける糖尿病網膜症市場の現在および将来の需要を強調する地域展望を取り上げます。さらに、著名な全地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場ハイライト
• 世界市場スナップショット

第3章 糖尿病網膜症：産業分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 業界動向
• ポーターのファイブフォース分析
• 市場魅力度分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 糖尿病網膜症の世界市場分析：タイプ別

• 概要：タイプ別
• 実績データと予測データ
• 分析：タイプ別
• 増殖糖尿病網膜症
• 非増殖糖尿病網膜症

第6章 糖尿病網膜症の世界市場分析：管理別

• 概要：管理別
• 実績データと予測データ
• 分析：管理別
• 抗VEGF薬
• ステロイド眼内注射
• レーザー手術
• 硝子体手術

第7章 糖尿病網膜症の世界市場分析：地域別

• 展望：地域別
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他のアジア太平洋
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他のラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他の中東・アフリカ

第8章 糖尿病網膜症企業の競合情勢

• 糖尿病網膜症市場の競合
• 提携・協力・合意
• 合併・買収
• 新製品の上市
• その他の開発

第9章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• Bayer AG
• ABBVIE INC.
• Novartis AG
• Oxurion NV
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company Ltd.
• Genentech Inc.

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Type (USD MN)
• Proliferative Diabetic Retinopathy Market Sales by Geography (USD MN)
• Non-proliferative Diabetic Retinopathy Market Sales by Geography (USD MN)
• Analysis Market by Management (USD MN)
• Anti-VEGF Market Sales by Geography (USD MN)
• Intraocular Steroid Injection Market Sales by Geography (USD MN)
• Laser Surgery Market Sales by Geography (USD MN)
• Vitrectomy Market Sales by Geography (USD MN)
• Global Diabetic Retinopathy Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Diabetic Retinopathy Report
• Market Research Process
• Market Research Methodology
• Global Diabetic Retinopathy Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Type
• Market Attractiveness Analysis by Management
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Type (USD MN)
• Proliferative Diabetic Retinopathy Market Sales by Geography (USD MN)
• Non-proliferative Diabetic Retinopathy Market Sales by Geography (USD MN)
• Global Market Analysis by Management (USD MN)
• Anti-VEGF Market Sales by Geography (USD MN)
• Intraocular Steroid Injection Market Sales by Geography (USD MN)
• Laser Surgery Market Sales by Geography (USD MN)
• Vitrectomy Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.08 BN by 2030 from USD 8.61 BN in 2022 with a CAGR of 7.26% under the study period 2023 - 2030.

Diabetic retinopathy is an eye disease linked to diabetes, impacting the retina-the light-sensitive tissue at the back of the eye. It stands as a prominent cause of vision impairment among individuals with diabetes. The condition develops gradually as elevated levels of blood sugar associated with diabetes cause damage to the small blood vessels within the retina.

MARKET DYNAMICS

The diabetic retinopathy market is driven by several key factors, with the increasing global prevalence of diabetes being a primary contributor. As diabetes remains a significant health concern, the rising incidence contributes to a growing population at risk of diabetic retinopathy, propelling the demand for diagnostic and treatment solutions. The pivotal role of technological advancements in diagnostic tools and imaging techniques is evident in their contribution to enhancing early detection capabilities. The emphasis on regular eye screenings and the integration of telemedicine in screening programs further expands accessibility, particularly in underserved areas. Pharmaceutical innovations, including intravitreal injections and medications targeting diabetic macular edema, contribute to the market's development by offering effective management options. The heightened awareness among healthcare professionals and patients about the importance of eye health in diabetes management encourages increased screenings and early intervention.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic retinopathy. The growth and trends of diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Proliferative Diabetic Retinopathy
• Non-Proliferative Diabetic Retinopathy

By Management

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Diabetic Retinopathy market include Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company Ltd., and Genentech, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Management
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY TYPE

• 5.1 Overview by Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Type
• 5.4 Proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions
• 5.5 Non-proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions

6 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY MANAGEMENT

• 6.1 Overview by Management
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Management
• 6.4 Anti-VEGF Historic and Forecast Sales by Regions
• 6.5 Intraocular Steroid Injection Historic and Forecast Sales by Regions
• 6.6 Laser Surgery Historic and Forecast Sales by Regions
• 6.7 Vitrectomy Historic and Forecast Sales by Regions

7 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE DIABETIC RETINOPATHY COMPANIES

• 8.1. Diabetic Retinopathy Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF DIABETIC RETINOPATHY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Bayer AG
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. ABBVIE INC.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Novartis AG
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Oxurion NV
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Sirnaomics
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Alimera Sciences
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Ampio Pharmaceuticals Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. BCNPeptides
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Kowa Company Ltd.
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Genentech Inc.
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies